JoVE Logo

S'identifier

6.5 : Renal Drug Excretion: Tubular Reabsorption

Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This process can either be active, commonly seen with endogenous substances like electrolytes and glucose, or passive, typical for many exogenous substances, including drugs. Active reabsorption is rare among drugs, with oxopurinol (a metabolite of allopurinol) being one of the few examples. Passive reabsorption is driven by concentration gradients established by back diffusion or reabsorption of water along with sodium and other inorganic ions.

Most drugs are weak acids or bases; their ionization level depends on pH. By altering the pH of urine, the reabsorption of these drugs can be hindered. When urine becomes alkaline, weak acidic drugs become predominantly ionized. Due to the decreased permeability of ionized forms through tubular cells, these drugs remain in the lumen and are ultimately expelled in the urine. This mechanism, known as 'ion trapping,' prevents reabsorption and enhances renal clearance of unwanted drugs. For example, in cases of an overdose of weakly acidic drugs, such as phenobarbital, treatment with bicarbonate is used to alkalinize the urine. This action ionizes the drug, impeding its back diffusion. Similarly, when dealing with an overdose of weakly basic drugs such as amphetamines, urine acidification is employed to ensure the ionized drug is not reabsorbed.

Tags

Renal Drug ExcretionTubular ReabsorptionGlomerular FiltrationDistal Convoluted TubulePassive ReabsorptionActive ReabsorptionDrug Half lifeLipophilic DrugsIon TrappingUrine PHRenal ClearanceWeak AcidsWeak BasesOverdose Treatment

Du chapitre 6:

article

Now Playing

6.5 : Renal Drug Excretion: Tubular Reabsorption

Pharmacokinetics: Drug Excretion and Clearance

88 Vues

article

6.1 : Drug Elimination: Overview

Pharmacokinetics: Drug Excretion and Clearance

979 Vues

article

6.2 : Elimination Kinetics: First-Order and Zero-Order

Pharmacokinetics: Drug Excretion and Clearance

395 Vues

article

6.3 : Renal Drug Excretion: Overview

Pharmacokinetics: Drug Excretion and Clearance

100 Vues

article

6.4 : Renal Drug Excretion: Glomerular Filtration

Pharmacokinetics: Drug Excretion and Clearance

130 Vues

article

6.6 : Renal Drug Excretion: Tubular Secretion

Pharmacokinetics: Drug Excretion and Clearance

114 Vues

article

6.7 : Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa

Pharmacokinetics: Drug Excretion and Clearance

132 Vues

article

6.8 : Hepatic Drug Excretion: Enterohepatic Cycling

Pharmacokinetics: Drug Excretion and Clearance

954 Vues

article

6.9 : Hepatic Drug Excretion: Influencing Factors

Pharmacokinetics: Drug Excretion and Clearance

79 Vues

article

6.10 : Drug Excretion: Pulmonary and Glandular Routes

Pharmacokinetics: Drug Excretion and Clearance

66 Vues

article

6.11 : Drug Excretion: Miscellaneous Routes

Pharmacokinetics: Drug Excretion and Clearance

34 Vues

article

6.12 : Drug Clearance: Overview

Pharmacokinetics: Drug Excretion and Clearance

46 Vues

article

6.13 : Clearance Models: Physiological Models

Pharmacokinetics: Drug Excretion and Clearance

45 Vues

article

6.14 : Clearance Models: Compartment Models

Pharmacokinetics: Drug Excretion and Clearance

47 Vues

article

6.15 : Clearance Models: Noncompartmental Models

Pharmacokinetics: Drug Excretion and Clearance

37 Vues

See More

JoVE Logo

Confidentialité

Conditions d'utilisation

Politiques

Recherche

Enseignement

À PROPOS DE JoVE

Copyright © 2025 MyJoVE Corporation. Tous droits réservés.